These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1392 related articles for article (PubMed ID: 30398102)

  • 1. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
    Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
    Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
    Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
    Cancer Biol Med; 2024 May; 21(6):451-72. PubMed ID: 38801082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next generation of immune checkpoint therapy in cancer: new developments and challenges.
    Marin-Acevedo JA; Dholaria B; Soyano AE; Knutson KL; Chumsri S; Lou Y
    J Hematol Oncol; 2018 Mar; 11(1):39. PubMed ID: 29544515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not All Immune Checkpoints Are Created Equal.
    De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
    Front Immunol; 2018; 9():1909. PubMed ID: 30233564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.
    Leone RD; Lo YC; Powell JD
    Comput Struct Biotechnol J; 2015; 13():265-72. PubMed ID: 25941561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.
    Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
    Wang L; Bai L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection.
    Sperk M; Domselaar RV; Neogi U
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.
    Samiei A; Gjertson DW; Memarzadeh S; Konecny GE; Moatamed NA
    Diagn Pathol; 2022 Sep; 17(1):70. PubMed ID: 36104728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.